Overview of the lifting of restrictions on A-shares by Zhitong | January 13.

According to Zhito Finance APP, on January 13, a total of 14 listed companies had their restricted stocks released, with a total market value of approximately 9.316 billion yuan. The specific status of the restricted stock release today is as follows: Stock Abbreviation Stock Code Type of Restricted Stock Number of Released Stocks Tai Mushi 001234 Pre-issue Shares Restricted Circulation 77.6 million Shanghai Bairun Investment Holding Group 002568 Stock-based Incentive Restricted Circulation 1.0696 million Ningbo Sanxing Medical Electric 601567 Stock-based Incentive Restricted Circulation 3.8059 million Ningbo Peacebird Fashion 603877 Stock-based Incentive Restricted Circulation 1.149 million Zhejiang Tiantai Xianghe Industrial 603500 Stock-based Incentive Restricted Circulation 1.138 million Haofan Biology 3

Zhitong FinanceJan 13 09:00

Haofan Bio (301393.SZ) will have 13.136 million restricted shares listed and become tradable on January 15.

Haofan Biological (301393.SZ) announced that the number of Shareholders whose restrictions on sales are lifted this time is 5, with a total number of shares being 1...

Zhitong FinanceJan 12 15:56

Haofan Biological (301393.SZ): Has repurchased a total of 1.0281 million shares.

Gelonghui reported on January 2 that Haofan Biotechnology (301393.SZ) announced that as of December 31, 2024, the company had repurchased a total of 1,028,148 shares through a dedicated repurchase securities Account via centralized bidding Trade, accounting for 0.95% of the company's current total share capital, with a highest Fill Price of 51.50 yuan per share, a lowest Fill Price of 33.46 yuan per share, and a total amount of 41.9958 million yuan (excluding transaction fees).

Gelonghui FinanceJan 2 20:25

The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

The weight loss sector of A-shares is generally up, Haofan Biotechnology rose more than 10%.

On November 27, Grinvest reported that Haofan Biotech rose over 10%, Nuotai Bio and Chongqing Pharscin Pharmaceutical rose over 4%, while Jiangsu Hengrui Pharmaceuticals, Shenzhen Salubris Pharmaceuticals, and Xinjiang Bai Hua Cun Pharma Tech also increased.

Gelonghui FinanceNov 27, 2024 09:40

Haofan Biology (301393.SZ): has accumulated repurchased 0.95% of shares

November 1st, Gelonghui丨Haofan Biology (301393.SZ) announced that as of October 31, 2024, the company has repurchased a total of 1,028,148 shares of the company through a repurchase special securities account in a centralized auction trading manner, accounting for 0.95% of the company's current total share capital. The highest fill price was 51.50 yuan per share, the lowest fill price was 33.46 yuan per share, and the total transaction amount was 41.9958 million yuan (excluding transaction costs).

Gelonghui FinanceNov 1, 2024 17:58